Overview

• The study published Sept. 2 in eBioMedicine reports an AUC of 0.92 with 91% sensitivity and 84% specificity in the validation cohort.
• The three-gene panel—TTC3, H4C5 and EPCAM—was selected from an initial pool of 815 prostate-specific genes and tested after a development phase on 341 specimens and a validation set of 1,055 specimens.
• Biomarker signals were present before prostatectomy and nearly absent after surgery, indicating a prostate tissue origin.
• The test retained accuracy in many PSA-negative cancers and differentiated malignancy from benign conditions such as BPH and prostatitis, outperforming PCA3 for BPH discrimination.
• Investigators have filed a patent and are pursuing independent validation and clinical assay development with support from Johns Hopkins Technology Ventures.